Key result
Serial drug testing guided by programmed ventricular stimulation fails to prevent recurrent arrhythmic events.
Why the study?
Does programmed ventricular stimulation and serial drug testing predict outcomes and guide therapy in patients with valvular heart disease presenting with ventricular tachyarrhythmias or syncope?
Population
97 patients with valvular heart disease presenting with sustained ventricular tachycardia, ventricular…
Design
Cohort
Follow-up
mean 51 months
Authors
Loading...
Serial drug testing by programmed stimulation appears unreliable for guiding therapy; leaves open its role in risk stratification for valvular heart disease patients.
Cohort (n=97)
Does programmed ventricular stimulation and serial drug testing predict outcomes and guide therapy in patients with valvular heart disease presenting with ventricular tachyarrhythmias or syncope?
Absolute Event Rate: 56% vs 53%
In patients with valvular heart disease and ventricular arrhythmias or syncope, programmed ventricular stimulation predicts adverse outcomes, but serial drug testing is unreliable for guiding therapy, supporting early consideration of ICD implantation.
Martínez‐Rubio et al. (1997) conducted a cohort in Valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope (n=97). Serial drug testing guided by programmed ventricular stimulation vs. No change in inducibility was evaluated on Recurrence of arrhythmic events. Serial drug testing guided by programmed ventricular stimulation was unreliable for guiding therapy, with arrhythmic events recurring in 56% of patients with suppressed inducibility vs 53% without.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: